WallStSmart
MLYS

Mineralys Therapeutics, Inc. Common Stock

NASDAQ: MLYS · HEALTHCARE · BIOTECHNOLOGY

$29.73
-5.43% today

Updated 2026-06-05

Market cap
$2.08B
P/E ratio
P/S ratio
EPS (TTM)
$-1.97
Dividend yield
52W range
$13 – $48
Volume
1.4M

Mineralys Therapeutics, Inc. Common Stock (MLYS) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item202020212022202320242025
Revenue$0.00$0.00$0.00$0.00$0.00$0.00
Revenue growth (YoY)
Cost of revenue$43000.00$59000.00
Gross profit$-43000.00$-59000.00
Gross margin
R&D$2.41M$16.31M$26.25M$70.36M$168.58M$132.01M
SG&A$532000.00$2.42M$5.23M$14.30M$23.82M$38.59M
Operating income$-2.94M$-18.73M$-31.48M$-84.66M$-192.40M$-170.60M
Operating margin
EBITDA$-3.31M$-19.38M$-31.48M$-84.66M$-192.36M$-170.54M
EBITDA margin
EBIT$-5.89M$-37.45M$-31.48M$-84.82M$-192.40M$-170.60M
Interest expense$115000.00$27000.00$1.68M
Income tax
Effective tax rate0.0%0.0%0.0%0.0%0.0%0.0%
Net income$-3.43M$-19.41M$-29.80M$-71.90M$-177.81M$-154.65M
Net income growth (YoY)-466.5%-53.5%-141.3%-147.3%+13.0%
Profit margin

Frequently asked questions

How much free cash flow does MLYS generate?

MLYS produced $-142.43M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is MLYS's balance sheet healthy?

MLYS holds $172.92M in cash and equivalents against — in long-term debt, on $646.69M of shareholder equity. That debt is best read against the cash flow the business throws off each year.